Stay updated on Pembrolizumab in Pediatric Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Pediatric Solid Tumors Clinical Trial page.

Latest updates to the Pembrolizumab in Pediatric Solid Tumors Clinical Trial page
- Check2 days agoChange DetectedThe two screenshots show only layout and visual styling differences; no changes to core study information, eligibility criteria, endpoints, or enrollment details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check9 days agoNo Change Detected
- Check30 days agoChange DetectedAdded a government operating-status notice and updated version to v3.2.0; removed the previous v3.1.0 tag.SummaryDifference2%

- Check37 days agoChange DetectedThe page now shows a new version (v3.1.0) and expanded contact numbers, replacing the old v3.0.2; core content is updated mainly through versioning and contact details.SummaryDifference0.0%

- Check52 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2 and the 'Back to Top' element was removed; no core content, pricing, stock, or time-slot information changed.SummaryDifference0.1%

- Check59 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.1%

- Check66 days agoChange DetectedThe web page has undergone significant changes, including the addition of new facility names and locations, as well as updates to disease categories and a new version revision. Notably, the previous entries for São Paulo, Brazil, and other locations have been removed.SummaryDifference4%

Stay in the know with updates to Pembrolizumab in Pediatric Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Pediatric Solid Tumors Clinical Trial page.